JP2017525755A - Ｈｅｒ２抗体−薬物抱合体 - Google Patents

Ｈｅｒ２抗体−薬物抱合体 Download PDF

Info

Publication number
JP2017525755A
JP2017525755A JP2017519448A JP2017519448A JP2017525755A JP 2017525755 A JP2017525755 A JP 2017525755A JP 2017519448 A JP2017519448 A JP 2017519448A JP 2017519448 A JP2017519448 A JP 2017519448A JP 2017525755 A JP2017525755 A JP 2017525755A
Authority
JP
Japan
Prior art keywords
linker
self
antibody
bond
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017519448A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017525755A5 (enExample
Inventor
リン，ロン−ファ
リン，シー−ヤオ
シー，ユー−チー
ホアン，チウ−チェン
リー，シュウ−ファ
ツァイ，ユー−イン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abgenomics International Inc
Original Assignee
Abgenomics International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abgenomics International Inc filed Critical Abgenomics International Inc
Publication of JP2017525755A publication Critical patent/JP2017525755A/ja
Publication of JP2017525755A5 publication Critical patent/JP2017525755A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6869—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of the reproductive system: ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017519448A 2014-06-20 2015-06-18 Ｈｅｒ２抗体−薬物抱合体 Pending JP2017525755A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462014912P 2014-06-20 2014-06-20
US62/014,912 2014-06-20
US201462015661P 2014-06-23 2014-06-23
US62/015,661 2014-06-23
PCT/US2015/036414 WO2015195904A1 (en) 2014-06-20 2015-06-18 Her2 antibody-drug conjugates

Publications (2)

Publication Number Publication Date
JP2017525755A true JP2017525755A (ja) 2017-09-07
JP2017525755A5 JP2017525755A5 (enExample) 2018-07-26

Family

ID=54936097

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017519448A Pending JP2017525755A (ja) 2014-06-20 2015-06-18 Ｈｅｒ２抗体−薬物抱合体

Country Status (16)

Country Link
US (1) US20160051695A1 (enExample)
EP (1) EP3157560A4 (enExample)
JP (1) JP2017525755A (enExample)
KR (1) KR20170063507A (enExample)
CN (1) CN106659783A (enExample)
AU (1) AU2015277100A1 (enExample)
BR (1) BR112016029588A2 (enExample)
CA (1) CA2952834A1 (enExample)
IL (1) IL249626A0 (enExample)
MX (1) MX2016017117A (enExample)
PH (1) PH12016502509A1 (enExample)
RU (1) RU2017101331A (enExample)
SG (2) SG11201610468XA (enExample)
TW (1) TW201625315A (enExample)
WO (1) WO2015195904A1 (enExample)
ZA (1) ZA201700306B (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018528162A (ja) * 2015-06-29 2018-09-27 イミュノジェン・インコーポレーテッド システイン改変抗体の複合体
US10953106B2 (en) 2015-02-16 2021-03-23 Lonza Ltd Antibodies
JP2021532807A (ja) * 2018-08-08 2021-12-02 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド Ｃｄ４７およびｈｅｒ２を標的とする組換え二機能性タンパク質

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6180408B2 (ja) 2011-06-13 2017-08-16 アブゲノミクス コーペラティフ ユー．エー． 抗ｐｓｇｌ−１抗体およびその使用
TWI716339B (zh) 2012-12-21 2021-01-21 荷蘭商台醫（有限合夥）公司 親水性自消耗連接子及彼等之共軛物
US9950077B2 (en) 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
ES2919323T3 (es) 2015-12-04 2022-07-26 Seagen Inc Conjugados de compuestos de tubulisina cuaternizados
US11661438B2 (en) * 2015-12-21 2023-05-30 Pfizer, Inc. Purification of antibody drug conjugates using a sodium phosphate gradient
IL260289B (en) 2016-01-08 2022-08-01 Bioalliance Cv Tetravalent anti-psgl-1 antibodies and uses thereof
CN107029244B (zh) * 2016-02-04 2021-04-27 浙江昭华生物医药有限公司 抗her2抗体-药物偶联物及其应用
US11938194B2 (en) * 2017-02-28 2024-03-26 Seagen Inc. Cysteine mutated antibodies for conjugation
SI3592393T1 (sl) 2017-03-10 2022-04-29 Quiapeg Pharmaceuticals Ab Sprostljivi konjugati
CN110869394A (zh) * 2017-06-16 2020-03-06 伊莱利利公司 工程改造的抗体化合物及其缀合物
SG10201801219VA (en) 2018-02-13 2019-09-27 Agency Science Tech & Res Anti-HER2 Antibodies
BR112020015071A2 (pt) * 2018-03-09 2021-01-05 Quiapeg Pharmaceuticals Ab Conjugados de anticorpos liberáveis
KR102871791B1 (ko) 2018-09-10 2025-10-15 미라티 테라퓨틱스, 인크. 병용 요법
EP3849660A1 (en) 2018-09-12 2021-07-21 QuiaPEG Pharmaceuticals AB Releasable glp-1 conjugates
KR20220003506A (ko) * 2019-03-22 2022-01-10 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 표적 분자의 변형을 위한 조성물 및 방법
CN115803345A (zh) * 2020-03-05 2023-03-14 Umc乌得勒支控股有限公司 靶向蛋白质降解的膜泛素连接酶
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
CN112618726B (zh) * 2020-12-21 2022-11-11 江南大学 一种抗体缀合物、增强抗体分子免疫效应功能的方法
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
KR20250169306A (ko) 2023-04-18 2025-12-02 아스트라제네카 아베 절단가능한 링커를 포함하는 접합체
WO2025059190A2 (en) * 2023-09-11 2025-03-20 Catena Biosciences, Inc. Polypeptide conjugation compositions and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012519711A (ja) * 2009-03-06 2012-08-30 アジェンシス，インコーポレイテッド ２４ｐ４ｃ１２タンパク質に結合する抗体薬物結合体（ａｄｃ）

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2489364E (pt) * 2003-11-06 2015-04-16 Seattle Genetics Inc Compostos de monometilvalina conjugados com anticorpos
ES2549077T3 (es) * 2004-04-07 2015-10-22 Genentech, Inc. Espectrometría de masas de conjugados de anticuerpos
AU2010270979B2 (en) * 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
GB0920127D0 (en) * 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
MA34277B1 (fr) * 2010-04-15 2013-06-01 Spirogen Developments Sarl Pyrrolobenzodiazépines et conjugués de celles-ci
CN106749665B (zh) * 2010-04-21 2021-03-26 辛塔佳有限公司 Cc-1065类似物和双功能接头的缀合物
CN103566377A (zh) * 2012-07-18 2014-02-12 上海博笛生物科技有限公司 癌症的靶向免疫治疗
TWI716339B (zh) * 2012-12-21 2021-01-21 荷蘭商台醫（有限合夥）公司 親水性自消耗連接子及彼等之共軛物
MX2015010146A (es) * 2013-02-08 2016-05-31 Novartis Ag Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
PT2948184T (pt) * 2014-01-10 2016-07-08 Synthon Biopharmaceuticals Bv Conjugados de anticorpo-fármaco de duocarmicina apresentando uma melhor atividade antitumoral in vivo.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012519711A (ja) * 2009-03-06 2012-08-30 アジェンシス，インコーポレイテッド ２４ｐ４ｃ１２タンパク質に結合する抗体薬物結合体（ａｄｃ）

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOCONJUGATE CHEM., vol. 21, JPN6017044715, 2010, pages 5 - 13, ISSN: 0004075983 *
CANCER CHEMOTHER PHARMACOL, vol. Vol.70, p.439-449, JPN6019027125, 2012, ISSN: 0004075984 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10953106B2 (en) 2015-02-16 2021-03-23 Lonza Ltd Antibodies
US11833222B2 (en) 2015-02-16 2023-12-05 Lonza Ltd CL and/or CH1 mutated antibodies for drug conjugation
JP2018528162A (ja) * 2015-06-29 2018-09-27 イミュノジェン・インコーポレーテッド システイン改変抗体の複合体
JP2021088581A (ja) * 2015-06-29 2021-06-10 イミュノジェン・インコーポレーテッド システイン改変抗体の複合体
JP2022163185A (ja) * 2015-06-29 2022-10-25 イミュノジェン・インコーポレーテッド システイン改変抗体の複合体
JP7441281B2 (ja) 2015-06-29 2024-02-29 イミュノジェン・インコーポレーテッド システイン改変抗体の複合体
JP2021532807A (ja) * 2018-08-08 2021-12-02 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） カンパニー リミテッド Ｃｄ４７およびｈｅｒ２を標的とする組換え二機能性タンパク質
US11453724B2 (en) 2018-08-08 2022-09-27 Immuneonco Biopharmaceuticals (Shanghai) Inc. Recombinant bifunctional protein targeting CD47 and HER2
JP7193058B2 (ja) 2018-08-08 2022-12-20 イミューンオンコ バイオファーマシューティカルズ （シャンハイ） インコーポレイテッド Ｃｄ４７およびｈｅｒ２を標的とする組換え二機能性タンパク質

Also Published As

Publication number Publication date
RU2017101331A (ru) 2018-07-23
KR20170063507A (ko) 2017-06-08
SG11201610468XA (en) 2017-01-27
ZA201700306B (en) 2019-06-26
SG10201811124YA (en) 2019-01-30
RU2017101331A3 (enExample) 2019-01-31
TW201625315A (zh) 2016-07-16
US20160051695A1 (en) 2016-02-25
WO2015195904A1 (en) 2015-12-23
MX2016017117A (es) 2018-01-12
BR112016029588A2 (pt) 2017-08-22
AU2015277100A1 (en) 2017-02-02
CA2952834A1 (en) 2015-12-23
PH12016502509A1 (en) 2017-04-10
EP3157560A1 (en) 2017-04-26
CN106659783A (zh) 2017-05-10
EP3157560A4 (en) 2018-02-21
IL249626A0 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
JP2017525755A (ja) Ｈｅｒ２抗体−薬物抱合体
JP6482471B2 (ja) 親水性の自壊性リンカー及びそのコンジュゲート
US9950077B2 (en) Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
JP2017523958A (ja) 抗ｃｄ２２抗体−薬物コンジュゲート及びその使用方法
CN119173279A (zh) 抗体-药物缀合物及其用途
HK1216640B (en) Hydrophilic self-immolative linkers and conjugates thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180618

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190716

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200228